Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EMTRICITABINE for Maternal exposure timing unspecified: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 34 adverse event reports in the FDA FAERS database where EMTRICITABINE was used for Maternal exposure timing unspecified.

Most Reported Side Effects for EMTRICITABINE

Side Effect Reports % Deaths Hosp.
Foetal exposure during pregnancy 609 16.4% 137 52
Drug resistance 370 10.0% 3 32
Virologic failure 331 8.9% 11 25
Immune reconstitution inflammatory syndrome 262 7.1% 49 140
Exposure during pregnancy 212 5.7% 19 37
Drug ineffective 196 5.3% 30 44
Pathogen resistance 166 4.5% 0 12
Viral mutation identified 161 4.3% 2 6
Maternal exposure during pregnancy 160 4.3% 26 49
Death 154 4.1% 154 24
Treatment noncompliance 136 3.7% 7 35
Treatment failure 133 3.6% 4 6
Premature baby 127 3.4% 21 14
Drug interaction 106 2.9% 5 34
Off label use 91 2.5% 45 60

Other Indications for EMTRICITABINE

Hiv infection (2,362) Product used for unknown indication (477) Antiretroviral therapy (170) Prophylaxis against hiv infection (167) Acquired immunodeficiency syndrome (49) Hepatitis b (46) Hiv-2 infection (37) Hiv infection who clinical stage iii (28) Chronic hepatitis b (26) Hepatitis c (24)

Other Drugs Used for Maternal exposure timing unspecified

VALPROATE (1,477) ADALIMUMAB (1,280) NATALIZUMAB (492) RITONAVIR (486) EMTRICITABINE\TENOFOVIR DISOPROXIL (333) LOPINAVIR\RITONAVIR (278) DIVALPROEX (254) INTERFERON BETA-1A (245) DIMETHYL (212) ATAZANAVIR (169)

Related Pages

EMTRICITABINE Full Profile All Maternal exposure timing unspecified Drugs EMTRICITABINE Demographics EMTRICITABINE Timeline